Sorry, you need to enable JavaScript to visit this website.

PRISTIQ® (desvenlafaxine succinate) Drug Interactions

7 DRUG INTERACTIONS

7.1 Drugs Having Clinically Important Interactions with PRISTIQ

Table 8: Clinically Important Drug Interactions with PRISTIQ
Monoamine Oxidase Inhibitors (MAOI)
Clinical ImpactThe concomitant use of SSRIs and SNRIs including PRISTIQ with MAOIs increases the risk of serotonin syndrome.
InterventionConcomitant use of PRISTIQ is contraindicated:
  • With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with PRISTIQ.
  • Within 14 days of stopping an MAOI intended to treat psychiatric disorders.
  • In a patient who is being treated with linezolid or intravenous methylene blue.
[see Dosage and Administration (2.7), Contraindications (4) and Warnings and Precautions (5.2)].
Examplesselegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue
Other Serotonergic Drugs
Clinical ImpactConcomitant use of PRISTIQ with other serotonergic drugs increases the risk of serotonin syndrome.
InterventionMonitor for symptoms of serotonin syndrome when PRISTIQ is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of PRISTIQ and/or concomitant serotonergic drugs [see Warnings and Precautions (5.2)].
Examplesother SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St. John's Wort
Drugs that Interfere with Hemostasis
Clinical ImpactConcomitant use of PRISTIQ with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of PRISTIQ on the release of serotonin by platelets.
InterventionClosely monitor for bleeding for patients receiving an antiplatelet or anticoagulant drug when PRISTIQ is initiated or discontinued [see Warnings and Precautions (5.4)].
ExamplesNSAIDs, aspirin, and warfarin
Drugs that are Primarily Metabolized by CYP2D6
Clinical ImpactConcomitant use of PRISTIQ increases Cmax and AUC of a drug primarily metabolized by CYP2D6 which may increase the risk of toxicity of the CYP2D6 substrate drug [see Clinical Pharmacology (12.3)].
InterventionOriginal dose should be taken when co-administered with PRISTIQ 100 mg or lower. Reduce the dose of these drugs by up to one-half if co-administered with 400 mg of PRISTIQ.
Examplesdesipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine

7.2 Drugs Having No Clinically Important Interactions with PRISTIQ

Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are mainly metabolized by CYP3A4 (e.g., midazolam), or for drugs that are metabolized by both CYP2D6 and CYP3A4 (e.g., tamoxifen, aripiprazole), when administered concomitantly with PRISTIQ [see Clinical Pharmacology (12.3)].

7.3 Alcohol

A clinical study has shown that PRISTIQ does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking PRISTIQ.

7.4 Drug-Laboratory Test Interactions

False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No